Inozyme Pharma Performance
Inozyme Pharma holds a performance score of 13 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 1.93, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Inozyme Pharma will likely underperform. Use Inozyme Pharma jensen alpha and the relationship between the value at risk and kurtosis , to analyze future returns on Inozyme Pharma.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Inozyme Pharma are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Inozyme Pharma showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 34.9 M |
Inozyme |
Inozyme Pharma Relative Risk vs. Return Landscape
If you would invest 98.00 in Inozyme Pharma on April 21, 2025 and sell it today you would earn a total of 302.00 from holding Inozyme Pharma or generate 308.16% return on investment over 90 days. Inozyme Pharma is currently generating 4.4665% in daily expected returns and assumes 25.7842% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Inozyme, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Inozyme Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Inozyme Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Inozyme Pharma, and traders can use it to determine the average amount a Inozyme Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1732
| Best Portfolio | Best Equity | INZY | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 25.78 actual daily | 96 96% of assets are less volatile |
Expected Return
| 4.47 actual daily | 90 90% of assets have lower returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average Inozyme Pharma is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Inozyme Pharma by adding it to a well-diversified portfolio.
Inozyme Pharma Fundamentals Growth
Inozyme Stock prices reflect investors' perceptions of the future prospects and financial health of Inozyme Pharma, and Inozyme Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Inozyme Stock performance.
| Return On Equity | -1.42 | ||||
| Return On Asset | -0.48 | ||||
| Current Valuation | 220.43 M | ||||
| Shares Outstanding | 64.56 M | ||||
| Price To Book | 8.12 X | ||||
| EBITDA | (104.03 M) | ||||
| Cash And Equivalents | 151.48 M | ||||
| Cash Per Share | 3.77 X | ||||
| Total Debt | 46.87 M | ||||
| Debt To Equity | 0.02 % | ||||
| Book Value Per Share | 0.49 X | ||||
| Cash Flow From Operations | (91.91 M) | ||||
| Earnings Per Share | (1.68) X | ||||
| Total Asset | 123.18 M | ||||
| Retained Earnings | (387.95 M) | ||||
Things to note about Inozyme Pharma performance evaluation
Checking the ongoing alerts about Inozyme Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Inozyme Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Inozyme Pharma is not yet fully synchronised with the market data | |
| Inozyme Pharma is way too risky over 90 days horizon | |
| Inozyme Pharma has some characteristics of a very speculative penny stock | |
| Inozyme Pharma appears to be risky and price may revert if volatility continues | |
| Inozyme Pharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (102.02 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Inozyme Pharma currently holds about 151.48 M in cash with (91.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.77. | |
| Over 94.0% of the company shares are owned by institutional investors |
- Analyzing Inozyme Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Inozyme Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Inozyme Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Inozyme Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Inozyme Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Inozyme Pharma's stock. These opinions can provide insight into Inozyme Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Inozyme Stock
If you are still planning to invest in Inozyme Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Inozyme Pharma's history and understand the potential risks before investing.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |